Treatments for important dermatology disorders

Historical Background

Dermadis was founded in February 2010 to firstly develop inhibitors of kallikreins in the dermatology field. The recent discoveries of the importance of kallikreins in skin diseases, and the potential of kallikrein inhibitors as therapeutic agents in dermatological disorders are the core business of Dermadis. Dermadis will also develop new lead compounds against other proteases to treat skin disorders using new technology platforms.